Sumitomo Pharma Co., Ltd. (FRA:DPM)
Germany · Delayed Price · Currency is EUR 12.30
-0.60 (-4.65%)
At close: Jan 28, 2026
Sumitomo Pharma Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 453,395 | 398,832 | 314,558 | 555,544 | 560,035 | 515,952 | |
Revenue Growth (YoY) | 21.65% | 26.79% | -43.38% | -0.80% | 8.54% | 6.88% |
Cost of Revenue | 184,809 | 153,437 | 126,577 | 178,919 | 157,127 | 137,773 |
Gross Profit | 268,586 | 245,395 | 187,981 | 376,625 | 402,908 | 378,179 |
Selling, General & Admin | 169,061 | 160,386 | 397,705 | 339,212 | 217,339 | 173,666 |
Research & Development | 41,000 | 49,865 | 112,637 | 131,858 | 94,903 | 132,682 |
Other Operating Expenses | -49,871 | 1,902 | 942 | -2,200 | -1,043 | 825 |
Operating Expenses | 160,190 | 232,372 | 543,117 | 502,974 | 342,941 | 323,880 |
Operating Income | 108,396 | 13,023 | -355,136 | -126,349 | 59,967 | 54,299 |
Interest Expense | -30,228 | -6,221 | -3,893 | -2,640 | -2,970 | -2,436 |
Interest & Investment Income | - | 1,421 | 2,839 | 5,486 | 1,175 | 1,153 |
Earnings From Equity Investments | 270 | -905 | - | - | - | - |
Currency Exchange Gain (Loss) | - | -4,942 | 32,829 | 26,308 | 24,530 | 8,037 |
Other Non Operating Income (Expenses) | - | -1,451 | -30 | -95 | -8 | -127 |
EBT Excluding Unusual Items | 78,438 | 925 | -323,391 | -97,290 | 82,694 | 60,926 |
Gain (Loss) on Sale of Investments | - | 13,537 | -224 | 24,735 | - | - |
Gain (Loss) on Sale of Assets | 16,686 | 3,149 | 501 | 24,635 | 267 | 16,925 |
Pretax Income | 95,124 | 17,611 | -323,114 | -47,920 | 82,961 | 77,851 |
Income Tax Expense | -14,968 | -6,024 | -8,185 | 48,794 | 42,361 | 41,022 |
Earnings From Continuing Operations | 110,092 | 23,635 | -314,929 | -96,714 | 40,600 | 36,829 |
Minority Interest in Earnings | - | -1 | -40 | 22,202 | 15,813 | 19,390 |
Net Income | 110,092 | 23,634 | -314,969 | -74,512 | 56,413 | 56,219 |
Net Income to Common | 110,092 | 23,634 | -314,969 | -74,512 | 56,413 | 56,219 |
Net Income Growth | - | - | - | - | 0.34% | 37.95% |
Shares Outstanding (Basic) | 397 | 397 | 397 | 397 | 397 | 397 |
Shares Outstanding (Diluted) | 397 | 397 | 397 | 397 | 397 | 397 |
EPS (Basic) | 277.11 | 59.49 | -792.79 | -187.55 | 141.99 | 141.50 |
EPS (Diluted) | 277.11 | 59.49 | -792.79 | -187.55 | 141.99 | 141.50 |
EPS Growth | - | - | - | - | 0.34% | 37.95% |
Free Cash Flow | 47,092 | 8,002 | -252,664 | 3,470 | 23,892 | 129,553 |
Free Cash Flow Per Share | 118.53 | 20.14 | -635.97 | 8.73 | 60.14 | 326.09 |
Dividend Per Share | - | - | - | 21.000 | 28.000 | 28.000 |
Dividend Growth | - | - | - | -25.00% | - | - |
Gross Margin | 59.24% | 61.53% | 59.76% | 67.79% | 71.94% | 73.30% |
Operating Margin | 23.91% | 3.26% | -112.90% | -22.74% | 10.71% | 10.52% |
Profit Margin | 24.28% | 5.93% | -100.13% | -13.41% | 10.07% | 10.90% |
Free Cash Flow Margin | 10.39% | 2.01% | -80.32% | 0.63% | 4.27% | 25.11% |
EBITDA | 130,002 | 38,585 | -317,371 | -85,086 | 98,315 | 76,972 |
EBITDA Margin | 28.67% | 9.67% | -100.89% | -15.32% | 17.55% | 14.92% |
D&A For EBITDA | 21,606 | 25,562 | 37,765 | 41,263 | 38,348 | 22,673 |
EBIT | 108,396 | 13,023 | -355,136 | -126,349 | 59,967 | 54,299 |
EBIT Margin | 23.91% | 3.26% | -112.90% | -22.74% | 10.71% | 10.52% |
Effective Tax Rate | - | - | - | - | 51.06% | 52.69% |
Advertising Expenses | - | 25,000 | 42,372 | 59,857 | 37,780 | 37,362 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.